A SKIN MICROBE SAMPLER AND RELATED METHODS
20230320707 · 2023-10-12
Inventors
Cpc classification
B33Y30/00
PERFORMING OPERATIONS; TRANSPORTING
B33Y80/00
PERFORMING OPERATIONS; TRANSPORTING
B29C33/42
PERFORMING OPERATIONS; TRANSPORTING
International classification
A61B10/02
HUMAN NECESSITIES
B29C33/42
PERFORMING OPERATIONS; TRANSPORTING
Abstract
The invention relates to a skin microbe sampler comprising: a plurality of solid microneedles extending from a support surface, wherein the microneedles are dimensioned to penetrate the epidermis and/or dermis layer of the skin to obtain microbes residing in the skin. In particular, in one embodiment, the microneedles comprise a cone shape that is substantially devoid of patterning on the surface of said cone shape, in another embodiment, the surfaces of the microneedles comprise an adhesion coating on their surfaces for enhancing adhesion of the microbes on the microneedles. Also provided are a method of sampling microbes residing in a skin, a method of making the microbe sampler, and a mold for making the microbe sampler. In particular, in one embodiment, the method of making the microbe sampler comprises 3D printing the solid microneedles and/or molding the solid microneedles from a negative imprint of the solid microneedles.
Claims
1. A skin microbe sampler comprising: a plurality of solid microneedles extending from a support surface, wherein the microneedles are dimensioned to penetrate the epidermis layer of the skin to obtain microbes residing in the skin.
2. The microbe sampler of claim 1, wherein the microneedles are configured to obtain microbes residing at a depth that is more than about 20 microns and no more than about 300 microns from the skin surface.
3. The microbe sampler of claim 1, wherein the microneedles are configured to obtain microbes residing beyond 50% of the depth of the stratum corneum of the epidermis.
4. The microbe sampler of claim 1, wherein the microneedles comprise a shape that tapers from a base to a tip.
5. The microbe sampler of claim 1, wherein the microneedles comprise a cone shape that is substantially devoid of patterning on the surface of said cone shape.
6. The microbe sampler of claim 1, wherein the microneedles have a needle height in the range of from about 1 mm to about 2.2 mm.
7. The microbe sampler of claim 1, wherein the microneedles have an aspect ratio in the range of about 0.5 to about 4.
8. The microbe sampler of claim 4, wherein the base comprises a width of from 0.5 mm to 1.5 mm.
9. The microbe sampler of claim 1, wherein the microneedles are spaced at a distance of from about 0.5 mm to about 2.0 mm from each other on the support surface.
10. The microbe sampler of claim 1, wherein the microneedles are disposed on the support at an average needle density of about 0.1 needles/mm.sup.2 to about 0.6 needles/mm.sup.2.
11. The microbe sampler of claim 1, wherein the microneedles are arranged in one or more 8×4 array(s).
12. The microbe sampler of claim 1, wherein the microneedles and the support surface form a unibody.
13. The microbe sampler of claim 1, wherein the microbe sampler is collapsible to reduce its original surface area for fitting into a chamber having an opening that is smaller than its original surface area.
14. The microbe sampler of claim 1, wherein the surfaces of the microneedles comprise an adhesion coating on their surfaces for enhancing adhesion of the microbes on the microneedles.
15. The microbe sampler of claim 1, wherein the microneedles are derived from 3D printing.
16. A method of sampling microbes residing in a skin, the method comprising: contacting the microbe sampler of claim 1 with the skin to allow the microneedles to penetrate the epidermis layer of the skin; allowing microbes residing in the skin to adhere to the microneedles that have penetrated the epidermis layer of the skin; and removing contact of the apparatus from the skin.
17. The method of claim 16, further comprising identifying the presence of microbes on the solid microneedles after removing contact of the microbe sampler from the skin.
18. A method of making the microbe sampler of claim 1, the method comprising: forming a plurality of solid microneedles that extends from a support surface, wherein the microneedles are dimensioned to penetrate the epidermis layer of the skin to obtain microbes residing in the skin, wherein the forming step comprises 3D printing the solid microneedles and/or molding the solid microneedles from a negative mold of the solid microneedles.
19. The method of claim 18, further comprising coating the microneedles with an adhesion coating on their surfaces for enhancing adhesion of the microbes on the microneedles.
20. A mold for making the microbe sampler of claim 1, the mold comprising: a negative imprint of the solid microneedles.
Description
BRIEF DESCRIPTION OF FIGURES
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083]
[0084]
[0085]
[0086]
[0087]
[0088]
[0089]
[0090]
[0091]
[0092]
[0093]
[0094]
[0095]
[0096]
[0097]
[0098]
[0099]
EXAMPLES
[0100] Current skin microbial sampling methods include swabbing, tape stripping or cup scrubbing which generate results that are highly dependent on the skin sampling method applied. Furthermore, the current sampling tools used in these methods sample solely from a uniform two-dimensional skin surface. However, contrary to popular belief, it is the inventors' understanding that microbial colonization (commensal bacteria and fungi) at the stratum corneum (SC) skin barrier is not uniformly two dimensional (i.e. only on one surface of the skin) but distributed across various layers and compartments.
[0101] Accordingly, as the currently available sample tools have limited capabilities to sample from deeper layers of the epidermis, it is believed that these tools are not able to achieve the comprehensive sampling depth required to obtain accurate diagnostics of the causative organisms which may reside deeper in the epidermis. In other words, the use of these existing sampling tools, which are incapable of capturing disease causing microbes that reside deeper in the epidermis, may lead to inaccurate (e.g. high rate of false negatives) or less representative results. This will in turn compromise the accuracy of disease diagnosis.
[0102] Improved sampling tools and methods could drive better treatment design and support a better understanding of skin diseases by enabling more accurate characterization of the skin microbiome in healthy and diseased skin as well as serving as a platform for diagnosing common microbial skin infections.
[0103] Thus, the inventors recognise the existence of a clinical need for reliable assessment of the microbiome in the superficial to deep layer of the SC.
[0104] As will be shown in the following Examples, through studies and experiments performed, the inventors have eventually developed an alternative skin microbe/microbiome apparatus/device which aims to address the limitations of the current sampling tools and methods that predominantly focus on the skin surface. Indeed, the development of standardized sampling tools that recognize the presence of microbial colonizers in multiple layers of the skin will enable more accurate and reliable diagnosis.
[0105] Example embodiments of the disclosure will be better understood and readily apparent to one of ordinary skill in the art from the following discussions and if applicable, in conjunction with the figures. It should be appreciated that other modifications related to e.g., structural changes may be made without deviating from the scope of the invention. Example embodiments are not necessarily mutually exclusive as some may be combined with one or more embodiments to form new exemplary embodiments. The example embodiments should not be construed as limiting the scope of the disclosure.
Example 1: Understanding Skin Microbial Colonization
[0106] In order to develop a unique and accurate alternative platform for the sampling of skin microbiome that is superior to that of conventional methods, it is imperative to first have a better understanding of skin microbial colonization.
[0107] 1. Commensal Bacteria and Fungi Reside at Different Levels of the Epidermis
[0108] The SC is the upper most layer of the epidermis and forms our first line of microbial defence on the skin. It comprises of corneocytes in layers 10-15 cells thick and 10-20 μm deep which are held together by tight epidermal junctions. Contrary to popular belief, microbial colonization at the SC skin barrier is not uniformly two dimensional but distributed across various layers and compartments.
[0109] This is nicely illustrated when visualizing OCT images of human skin (
[0110] Without being bound by theory, it is believed that bacteria are not homogenously distributed in the SC but vary with superficial and deeper layers of the skin. Using serial tape stripping methods, it has been shown that a majority of bacteria populate the upper layers of the SC and that lower layers are generally sterile.
[0111] Species such as Staphylococcus aureus strains associated with atopic dermatitis have been observed to increase in relative abundance in deeper layers of the skin. It has also been demonstrated that that bacterial species composition varies with the thickness of the SC, the presence of hair follicles and other axillary appendages.
[0112] Therefore, a reliable assessment of the microbiome in the superficial to deep layer of the SC may eventually allow a more accurate and reliable diagnosis of skin health to be provided.
[0113] 2. The Skin Microbiome is Three Dimensional and Varies with Skin Layer and Sampling Methods
[0114]
[0115]
[0116] Fungal counts decreased with each successive layer of the skin but did not decrease further after the 30.sup.th tape strip.
[0117] 2A. Glabella Layer Specific qPCR Copy Number Quantitation for Common Skin Microbes from Selected Samples
[0118] 80× tape strip pressings were obtained from the same region of the Glabella skin in a series of 4×20 pressings to probe microbe density across the layers. The results obtained for M. restricta, S. epidermidis and P. acnes are shown in
[0119] 3. Microbial Species Varying Over Different Layers of the SC
[0120] Species specific primers for Staphylococcus epidermidis, Staphylococcus aureus, Malassezia restricta and Malassezia globosa were used to discriminate commensal skin bacterial and fungi. A uniform 70% decrease in bacterial and fungal species counts was observed from the 10th to the 30th tape strip. However, the proportions of different bacterial and fungal species were observed to fluctuate from 10-50% of their maximal counts from a serial strip depth of 30 to 80× (
[0121] 4. Microbial Capture is Dependent on Sampling Method
[0122] The inventors have established that in addition to culture conditions, the sampling and culture of primary Malassezia fungal isolates is highly dependent on sampling methods. E.g. it is critical that the surface of the skin is not disinfected with 70% ethanol prior to skin swabbing, contrary to what is recommended in some clinical settings. Furthermore, the choice of diagnostic tool (e.g. brand/type of commercial swab) also significantly affected microbial recovery and yield (
[0123] With a better understanding of the microbial colonization of the skin and how microbial capture may be affected, the inventors then proceeded to devise alternative embodiments of a microneedle-based sampler as will be shown in the Examples below, which will represent a unique and accurate platform for the sampling of skin microbiome. To support the feasibility of this approach, the inventors also have performed some studies with results as illustrated in the Examples below.
Example 2: 3D-Printed Microneedle Patch (MNP)
[0124] Proposed microneedle patch designs Microneedles are three-dimensional (3D) microstructures with microscale projections (e.g., <1000 μm) which are designed to overcome the skin barrier to deliver active molecules in a minimally-invasive manner intradermally by piercing or reversible disruption of the SC.
[0125] While some processes can potentially give rise to microneedles with high consistency, they have limited flexibility in terms of the microneedle design. For example, when one type of master template with standard needle lengths and spacing is used as a mold to produce the entire batch of microneedles, it is technically challenging to fabricate microneedles of various geometries such as shape, length, aspect ratio and needle spacing.
[0126] Specific microneedle architecture has a direct and critical impact on the quantity of microbial material extracted from the skin. Therefore, it is believed that it is important to fabricate microneedles with customisable geometry and architecture to capture microbial load in the skin layers.
[0127] 3D printing is one method that has the potential to overcome the limitations of conventional methods because it enables the rapid and facile fabrication of customisable prototypes with complex geometries designed using computer-aided design (CAD) programs. However, even with 3D printing, it may not be straightforward to fabricate microneedles of good resolutions e.g. resolution of printed needles can be poor (the tips were not sharp). Attempting to improve resolution by including a post-printing step of chemical etching may also not be effective as the final printed prototypes may still not well-defined and needles with consistent shapes may not be easily attainable due to the etching step. 3D printing by photopolymerization strategies led to more well-defined microneedles.
[0128] In this Example, the inventors have successfully adopted 3D printing for the fabrication of customizable, complex architectures, for the microneedle patch manufacture.
[0129] In this Example, microneedle patches (i.e., skin microbe samplers) were designed with the following aims: (1) To penetrate the stratum corneum (SC) for three-dimensional microbial capture; and (2) To maximize microbial capture.
[0130] Without being bound by theory, it is believed that the design of the microneedle patch will directly impact the microbial load that is extracted by the needles.
[0131] Micro-patterning grooves on a conical surface of 25-30 μm in diameter were envisaged to enhance microbial uptake compared to purely conical ones. To this end, conical needles (i.e., solid microneedles) with patterned surfaces to penetrate the surface of the skin (e.g., penetrate the epidermis layer of the skin) and enable increased microbial capture (i.e., to obtain microbes residing in the skin) via ridges/grooves and large surface area for trapping microbiological material were designed.
[0132]
[0133] The tunability and customizability of 3D printing by optimizing the following parameters—needle spacing/density, needle height, thickness of the backing and surface functionalization (e.g., adhesives, in situ hybridization probes) were also be investigated.
[0134] 3D Printing Feasibility and Prototyping
[0135] The following fabrication methods were considered for the approach—(1) Fused deposition modelling (FDM) and (2) Stereolithography (SLA).
[0136] In this Example, a key consideration for 3D microneedle printing is being able to print with high definition and reproducibly at good resolution. To evaluate this across different platforms, CAD software was used to design a test prototype. As shown in
[0137] As shown in
[0138] On the other hand, as shown in
[0139] Under high magnification, a reproducible and defined screw pattern as well as variable needle heights were observed (see
[0140] In this Example, other materials may also be used for 3D printing. For example, the materials may be chosen from the library of biocompatible medical device Class I or II printing materials, i.e., two candidates are Freeprint® temp from DETAX or E-Dent 400 from EnvisionTEC. These materials are FDA-approved for use in dental applications including surgical guides, prosthesis, dentures and aligners.
[0141] Testing of Patch Sub-Epidermal Penetration on Porcine Skin
[0142] To assess the penetration of SLA printed microneedles patches on the skin, the prototype was applied to strips of porcine skin to assess their depth penetration and ability to pick up microbes from the skin, as shown in
[0143] As shown in
[0144] As shown in
[0145] In this Example, modifications may be made to optimize needle length and patterning to increase microbial capture. Further, species specific genomic tools may be developed for concurrent detection of different microbial species. This can be based on the library of DNA sequences derived from primary microbial isolates from healthy volunteers.
[0146] The Example described aims to provide novel microneedle patch designs and novel primer sequence and tools for species-specific microbial detection. Advantageously, embodiments of the present disclosure provide a huge improvement over conventional sampling tools. This is because embodiments of the 3D printed microneedle patch disclosed herein provide more accurate and reliable sampling by enabling 3-dimensional sampling in the deeper layers of the skin as currently available sampling tools tend to only cover the skin surface.
[0147] In the Example described, the microneedle patch advantageously is minimally invasive and only for transient use (<1 minute).
Example 3: 3D-Printed Microneedle Patch (MNP)
[0148] In this Example, another example of a 3D-printed microneedle patch (i.e., a skin microbe sampler) is provided.
[0149] 3D Printing of MNPs with Different Design Parameters
[0150] In this Example, MNPs of various designs based on an FDA class 2a biocompatible resin were produced. As shown in
[0151] In this Example, two parameters were varied—the needle topography (cone-, screw- or spike-patterned needle, as shown in
[0152] In Vitro Testing of MNP Using Sensitive Microbial Molecular Detection Methods
[0153] In order to validate the efficacy of the MNP sampling approach, it was necessary to develop de novo sensitive and specific methods for the sensitive and specific detection of skin commensal microbes. This was in the form of genus and species-specific primers for real-time quantitative PCR. This approach was tested and validated. Table 1 provides a summary of primer sets used for the detection of commensal skin microbes as a validation of MNP sampling efficacy.
TABLE-US-00001 TABLE 1 Summary of primer sets used for the detection of commensal skin microbes as a validation of MNP sampling efficacy. Primer Set Limits of Limits of Detection Quantitation Colony Forming Colony Forming Bacteria Units (CFU) Units (CFU) Source Staphylococcus 25 CFU 25 CFU Published epidermidis Staphylococcus 5 CFU 12 CFU Published aureus Limits of Limits of Detection Quantitation Malassezia ITS copy # ITS copy # Source M. restricta 4.01 9.68 In-house M. globosa 2.77 6.63 Published M. sympodialis 4.10 16.93 Published M. Slooffiae 23.44 29.51 In-house design M. furfur 1.56 5.20 In-house design
[0154] Assessing MNP Efficacy Using Porcine Skin
[0155] An assay using genus and species-specific primers for real-time quantitative PCR was used for the quantification of microbial extraction from mock communities of bacteria and fungi on porcine skin. The following were assessed—(1) the effect of topographical features of MNP needles (cone, spike, screw); and (2) the effect of needle lengths of MNPs influencing microbial pick-up on mock skin microbiome communities comprising of S. epidermidis and Malassezia.
[0156] As shown in
[0157] Methods
[0158] 1) 3D Printing of MNPs
[0159] MNPs of various needle lengths and topographies were designed using open-source program TinkerCAD. The designs were exported as .stl files and subsequently printed using the Dental LT resin on a Form 2 desktop printer (FormLabs). After printing, the prototypes were cured and rinsed with isopropyl alcohol to remove any unreacted resin.
[0160] 2) Strains and Growth Conditions
[0161] Malassezia reference strains, as listed in Table 2, were obtained from Centraalbureau voor Schimmelcultures (CBS) culture collection. Fresh Malassezia sp. reference strains were maintained in modified Dixon broth (mDixon). Staphylococcus epidermidis was maintained in LB broth, Miller (Millipore, 2768346).
TABLE-US-00002 TABLE 2 Reference strains of microbes Genus Species Reference strain Malassezia globosa CBS 7966 restricta CBS 7866 sympodialis CBS 42132 Staphylococcus epidermidis ATCC 12228
[0162] 3) Primers and PCR/qPCR Conditions
[0163] The list of primers used in the study is listed in Table 3. In quantitative PCR, the reaction mixture was pre-heated to 95.0° C. for 60 seconds, and then 95.0° C. for 15 seconds, and 60.0° C. for 10 seconds for 40 cycles in a two-step amplification process. In PCR, the reaction mixture was pre-heated as per Platinum® Taq DNA Polymerase (ThermoFisher, 10966018) to 94° C. for 5 minutes, then 94.0° C. for 30 seconds, 60.0° C. for seconds and 72.0° C. for 1 minute, repeat for 30 cycles. Lastly, the reaction mix was maintained at 72.0° C. for 7 minutes and cooled to 4° C. indefinitely until further processing was required.
TABLE-US-00003 TABLE 3 List of primers Expected product Primers Forward sequence (5′-3′) Reverse sequence (5′-3′) size (bp) VSH-Globosa GTGAATTGCAGAATTCCGTGAAT GAGCTTTTTCTAGAGAAGAAAAG 187 4F2R- GTGAATTGCAGAATTCCGTG AGACACAACCAAACATTCCTC 322 Restricta VSH- GTGAATTGCAGAATTCCGTGAAT TACAATCCCCAGGCAGCAA 171 Sympodialis SE1-F1R1 ATCAAAAAGTTGGCGAACCTTTTCA CAAAAGAGCGTGGAGAAAAGTATCA 124
[0164] 4) Preparation of Mock Community
[0165] Healthy cultures of cells were incubated for 48 to 96 hours prior to conducting the experiments. The OD.sub.600 was then measured by a ThermoFisher MultiskanSky spectrophotometer on 100 μL of neat S. epidermidis culture. Malassezia sp. cultures—CBS 7966, CBS 7877 and CBS 42132 were diluted 10-fold in Dulbecco PBS (ThermoFisher, 21300025) before measurement. All spectrophotometer measurements were conducted in triplicates. The mock community was then prepared by mixing appropriate volumes of the different cells and diluting respectively with dPBS so that the final OD.sub.600 of S. epidermidis is 0.1, CBS7966 0.05, CBS7877 0.05 and CBS42132 0.05.
[0166] 5) Sampling on Pig Skin and Quantitative PCR Analysis
[0167] To simulate skin sampling condition, four mL of mock community prepared was smeared onto a sheet of pig (Sus domesticus) skin not exceeding 10 cm in length and width and allowed to settle on the pig skin for 15 minutes. Subsequently, the mock community was decanted and allowed to dry for 30 minutes. The skin was then sampled with the respective methods, i.e., each MNP was pressed on the skin and held firmly for seconds, the tape-strips were applied for 25 consecutive times while the swabs were applied in an orbital manner for 3 cycles. An MNP with only the base (without needles) was used as negative control. After collection, the samples were immersed in 1 mL of DNA extraction buffer with 20 μg/ml of proteinase K (Vivantis, PC0712) and incubated at 56° C. for 18 hours at 500 rpm and heated to 94° C. for 10 minutes. Genomic DNA was extracted with filter sterilised SDS surfactant (Sigma, 71729), glass beads (Sigma, G8772) and phenol-chloroform isoamyl alcohol (Sigma, P3803) and vigorously vortexed and iced. Supernatant with gDNA was pipetted and allowed to precipitate in 100% EtOH (Sigma, E7023) for 24 hours. A quantitative PCR with a standard curve of plasmids at tenfold dilutions was performed against phenol-chloroform isoamyl-extracted DNA using Luna Universal qPCR Master Mix (New England Biolabs, M3003S) using the Agilent AriaMx Real-Time PCR system. The efficacy of sampling was determined by fold-change detection with respect to control.
Example 4: 3D-Printed Trans-Epidermal Microprojection Array (MPA)
[0168] In this Example, a 3D-printed trans-epidermal microprojection array (MPA) (i.e., a skin microbe sampler) is provided.
[0169] Method of Manufacturing a 3D-Printed Trans-Epidermal Microprojection Array (MPA) and Workflow for Sampling of Human Scalp Microbe
[0170] An exemplary method of designing and manufacturing the 3D-printed trans-epidermal microprojection array (MPA) and a workflow for sampling of human scalp microbe are shown in
[0171] In the method 1100, at step 1102, a CAD design of a microneedle sampling tool is designed. The design of the microneedle sampling tool 1102A comprises a plurality of solid microneedles 1102B that extend from a support surface (of a support 1102C), wherein the microneedles 1102B are dimensioned to penetrate the epidermis layer and the dermis layer of the skin to obtain microbes residing in the skin.
[0172] At step 1104, based on the CAD design at step 1102, the microneedle sampling tool is 3D-printed (see 3D-printed microneedle sampling tool 1104A). Step 1104 may alternatively involve forming the microneedle sampling tool (including the solid microneedles) from a negative mold thereof.
[0173] In this Example, the 3D-printed microneedle sampling tool 1104A is collapsible (i.e., may be separated into half or into two pieces) by folding in the direction of arrows 1104B and 1104C, and along the dotted line 1104D. The 3D-printed microneedle sampling tool 1104A has a plurality of solid microneedles 1104E in a cone shape.
[0174] Next, at step 1106, for sampling of human scalp microbiome, the 3D-printed microneedle sampling tool 1104A is placed onto a scalp (skin) of a subject (e.g., a human subject). Contacting the microneedle sampling tool 1104A with the scalp allows the microneedles to penetrate through the epidermis layer 1106A of the skin and to also penetrate (or access) the dermis layer 1106B, so as to obtain microbes (e.g., bacterium 1106C and fungus 1106D) residing in the epidermis layer 1106A and/or the dermis layer 1106B. In particular, the 3D-printed microneedle sampling tool 1104A is capable of obtaining microbes residing in the stratum corneum (SC) 1106E of the epidermis layer 1106A and in the sweat glands 1106F and hair follicles 1106G. In this Example, the 3D-printed microneedle sampling tool 1104A does not interact with the sebaceous glands 1106H and the blood vessels 11061. After allowing contact for a period of time, the microneedle sampling tool 1104A is removed from the scalp (skin). In various embodiments, each MPA may be applied for about five seconds. The MPA may also be applied for about one second, about two seconds, about three seconds, about four seconds, about six seconds, about seven seconds, about eight seconds, about nine seconds or about ten seconds.
[0175] At step 1108, the 3D-printed microneedle sampling tool 1104A is separated into two equal pieces and fitted into a (one) 2-mL Eppendorf tube, which is amenable to DNA extraction using minimal buffer, thereby increasing the concentration for downstream processing by real-time PCR and amplicon sequencing.
[0176] At step 1110, the obtained sample is processed.
[0177] At step 1112, the data obtained is analysed.
[0178] Effect of MPA Size, Density and Topography on Microbe Extraction in an Ex Vivo Porcine Skin Model
[0179] The effect of MPA size, density and topography on microbe extraction in an ex vivo porcine skin model was evaluated.
[0180] To evaluate the effect of MPA size and density, three different types of MPA were compared, namely, a MPA with has a length A of 11 mm and with a 4×4 array of microprojections (as shown in
[0181] Amongst the three different types of MPA described above, as shown in
[0182] Next, to evaluate the effect of MPA topography, the following four types of MPA were compared: a base (i.e., a base without any microprojections and with a length of 22 mm) as control, a MPA with a length D of 22 mm and with a 8×4 array of screw-patterned microprojections (as shown in
[0183] Amongst the different types of MPA described above, as shown in
[0184] It was previously hypothesized that patterning could increase pickup/enhance microbial uptake. However, the inventors have surprisingly found that this was not the case, i.e., non-patterned microprojections were more effective. This was an unexpected finding. Without being bound by theory, it is believed that one possible reason may be related to the penetration depth. The patterned surface with grooves seemed to hinder the penetration of the MPA. In other words, depth penetration of the MPAs seemed to be reduced as a result of topographical changes. As shown in
[0185] Effect of Microprojection Heights on Skin Penetration in Porcine Skin Ex Vivo
[0186] The effect of microprojection heights on skin penetration in porcine skin ex vivo was also evaluated.
[0187] To this end, three different types of 3D-printed MPAs were compared, namely, 3D-printed MPAs with cone-patterned microprojections of 1.0 mm, 1.2 mm and 1.5 mm (as shown in
[0188] As shown by the graph in
[0189] Sampling of Microbiome
[0190] To compare the different sampling approaches (i.e., swab, microneedle/MPA and tape strip), Amplicon sequencing of fungal ITS regions and bacterial 16S regions were performed for species comparison, as well as for investigating species diversity and clustering.
[0191] The results are shown across
[0192] Further additional data in relation to the results are shown in Table 4.
TABLE-US-00004 TABLE 4 Positive sampling rate for detection ITS fungal and 16S bacterial amplicons. ITS fungal positive 16S bacterial positive Swab 13/29 (44.8%) 15/29 (51.7%) MPA 15/29 (51.7%) 13/29 (44.8%) Tape strip 3/29 (10.3%) 3/29 (10.3%)
[0193] Effect of Microprojection Heights on Microbe Extraction in an Ex Vivo Porcine Skin Model
[0194] The effect of microprojection heights in the range of 1.0 mm to 1.5 mm on microbe extraction in an ex vivo porcine skin model was evaluated.
[0195] To this end, three different types of 3D-printed MPAs were compared, namely, 3D-printed MPAs with cone-patterned microprojections of 1.0 mm, 1.2 mm and 1.5 mm (herein referred to as “C_1.0”, “C_1.2” and “C_1.5” respectively).
[0196] As shown by the graphs in
[0197] Based on the above results, MPAs with a microprojection height of 1.2 mm for example can be used (e.g., over MPAs with microprojection height of 1.5 mm) without a reduction in efficacy of the MPAs. This may be advantageous in that MPAs with microprojection heights of 1.2 mm may cause less discomfort (e.g., to human subjects) than MPAs with microprojection heights of 1.5 mm.
[0198] Collapsible Trans-Epidermal MPA Design
[0199] In this Example, a collapsible trans-epidermal MPA has been described.
[0200] The trans-epidermal MPA is collapsible along the dotted line 1902 shown in
[0201] Efficacy of Various Sampling Tools in Extraction of Common Skin Microbes from Selected Human Samples
[0202] The efficacy of various sampling tools (i.e., swab, tape strip and MPA) in extracting skin microbes from selected human samples, namely, M. restricta, M. globosa, S. epidermidis and P. acnes was investigated.
[0203] From the results shown in
[0204] OTU Copy Number Comparisons of Representative Fungal and Bacterial Species Derived from Amplicon Sequencing
[0205] Fungal OTU copy numbers obtained for Malassezia spp. (Basidomycota) and Aspergillus spp. (Ascomycota) for different sampling methods (i.e., swab, MPA and tape strip) are shown in
[0206] The above data reflects/correlates well with the abundance data shown in
[0207] Bacterial OTU copy numbers for Streptococcus spp. (Firmicutes), Pseudomonas spp. (Proteobacteria) and Mycobacterium spp. (Actinobacteria) for different sampling methods (i.e., swab, MPA and tape strip) are shown in
[0208] The Examples show that embodiments of the skin microbe sampler disclosed herein provide a unique form of skin diagnostic device which offers a disruptive technology among the conventional tools for microbe/microbiome sampling (e.g., swabbing or tape stripping) and open up a new market for such products in the future. Embodiments of the skin microbe sampler disclosed herein represent an easily translatable technology with huge commercial potential. The huge improvements in accuracy and reliability over current devices will be attractive, especially appealing to developed countries with high incidences of microbiological infections, e.g. Singapore and USA since it can still be produced at competitive pricing. Furthermore, since embodiments of the skin microbe sampler disclosed herein are minimally invasive and only for transient use (<1 min), they would be categorized under Class A medical device by the Health Sciences Authority of Singapore (HSA). This is the class of regulated devices with the lowest risk and the approval process would require simple biocompatibility and functional tests (relatively small regulatory hurdle). These validation studies can be done by sampling the skin of human volunteers.
[0209] It will be appreciated by a person skilled in the art that other variations and/or modifications may be made to the embodiments disclosed herein without departing from the spirit or scope of the disclosure as broadly described. For example, in the description herein, features of different exemplary embodiments may be mixed, combined, interchanged, incorporated, adopted, modified, included etc. or the like across different exemplary embodiments. The present embodiments are, therefore, to be considered in all respects to be illustrative and not restrictive.